A peer-reviewed study found that the platform identified 57% more proteins than bulk methods and differentiated hepatocellular carcinoma from cirrhosis in plasma samples.
Mayo Clinic and Thermo Fisher Scientific have launched Precure, a joint venture to analyze one million biospecimens using multi-omics data and AI for early disease biomarker discovery.
AI models analyzing routine H&E slides can identify genomic alterations and immune patterns in NSCLC, supporting biomarker discovery and patient stratification, according to studies to be presented by Lunit at WCLC 2026.
Amsbio has launched synthetic cell mimic controls for flow cytometry, aiming to improve lot-to-lot consistency and reproducibility in diagnostics and cell therapy manufacturing.
Read More
Tel Aviv University researchers have developed a low-cost blood test that detects lung cancer by analyzing optical DNA fingerprints, achieving 93.1% sensitivity and 90.3% specificity.
Read More
Researchers at MUSC Hollings Cancer Center have developed the ADLiB liquid biopsy platform, which uses machine learning to prioritize lymphoma diagnosis, identifying high-risk patients with up to 95% accuracy.
Read More
VolitionRx has published peer-reviewed data on its Capture-Seq technology, reporting over 99% pure ctDNA isolation from plasma and 95% detection of early-stage cancers in validation cohorts.
Read More
Caris Life Sciences has launched in-house PTEN IHC testing to identify prostate cancer patients eligible for FDA-approved, biomarker-guided therapy, supporting precision treatment for PTEN-deficient mAPMN/S prostate cancer.
Read More
The funding will support the expansion of the Syn-One Test, a skin biopsy-based laboratory developed test for neurodegenerative diseases.
Read More
Labcorp is offering nationwide access to Roche’s FDA-approved VENTANA PTEN (SP218) RxDx Assay, the first IHC companion diagnostic to identify PTEN protein loss in prostate cancer and guide eligibility for combination therapy with capivasertib.
Read More
10x Genomics and Lausanne University Hospital have begun a multi-year study using single cell and spatial technologies to identify biomarkers predicting treatment response in patients with advanced solid tumors.
Read More
RNA-based testing improves detection of MET exon 14 skipping in NSCLC, identifying mutations missed by DNA-only assays, according to new research. Findings may impact eligibility for targeted therapies.
Read More
USC researchers report that two blood tests, Lumipulse G p-tau217/β-Amyloid 1-42 and PrecivityAD2, can accurately detect Alzheimer’s pathology in patients with Down syndrome.
Read More
The 21-month clinical research study with Imperial College London will assess the diagnostic value of a lateral flow test for active neutrophil elastase.
Read More
ALZpath and Alamar Biosciences have expanded their partnership, granting Alamar commercial rights to use ALZpath’s pTau217 antibody in clinical blood tests for Alzheimer’s disease.
Read More
Researchers from Charité – Universitätsmedizin Berlin report that steatotic liver disease subtypes often shift over time, with 36% of MetALD patients reclassified within six months, suggesting a need for dynamic disease monitoring.
Read More
A new study in The Journal of Nuclear Medicine reports that a noninvasive DNA blood test can help select advanced prostate cancer patients most likely to benefit from 223Ra radiopharmaceutical therapy and monitor treatment response.
Read More
Behavioral Diagnostics and Versiti Clinical Trial Solutions have partnered to provide epigenetic assays for objective smoking and alcohol exposure screening in clinical trials, aiming to improve participant risk assessment and data reliability.
Read More